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Pathogenesis of congenital cytomegalovirus infection
of the central nervous system
Abstract
Human Cytomegalovirus (HCMV) is the leading viral cause of congen-
ital infections in the central nervous system (CNS). HCMV infection in the
brain is accompanied with wide spread encephalitis and developmental ab-
normalities of newborn brain which may result in severe long term se-
quelae. Due to species specificity of CMVs, animal models are frequently
used for HCMV pathogenesis research. Murine cytomegalovirus (MCMV)
shares many biological similarities to HCMV and therefore mouse model is
most frequently used to study the pathogenesis of congenital HCMV infec-
tion. MCMV establishes productive infection in the brain parenchyma of
newborn mice which leads to extensive non-necrotizing multifocal wide-
spread encephalitis characterized with infiltration of both components of
innate and adaptive immunity. As a result, impairments in postnatal devel-
opment of mouse cerebellum lead to long term motor and sensor disabili-
ties. Extrapolated data from murine model indicate that CMV infection
and inflammation in the developing CNS alter normal tissue programs in
developing brain and, thus, are responsible for the neurological disorders
associated with congenital CMV infection. High rate of sequelae follow-
ing congenital CMV infection and insufficient antiviral therapy in peri-
natal period assigned CMV-specific vaccine as the highest priority of mod-
ern medicine.
CMV INFECTION: PUBLIC HEALTH ISSUE
Cytomegalovirus (CMV) is a large DNA virus which belongs to afamily of b herpesviridae. Human cytomegalovirus (HCMV) is
ubiquitous pathogen in humans, infecting over 50% of the world popu-
lation (1). Like all herpes viruses, human CMV (HCMV) establishes
life-long latency in infected host and can be reactivated depending on
the host immune status. In immunocompromised patients and trans-
plant recipients HCMV acts as a devastating opportunistic agent in-
ducing life treating pneumonitis or encephalitis. Public health impor-
tance of HCMV infection is especially highlighted in newborns and
prematures: HCMV is the leading viral cause of congenital infections
resulting in long term neurological defects (2, 3). Intrauterine HCMV
infection usually occurs during primary maternal infection when the
rate of mother to fetus virus transmission is over 40% (4) with the 20%
to 25% risk of postnatal development of neurological impairments in
infected infants (5). Although most of the infected newborns have
asymptomatic disease, the majority of children who suffer from symp-
tomatic HCMV infection and, even more importantly, 10–15% of chil-
dren with asymptomatic HCMV disease will develop severe neurologi-
ESTER PERNJAK PUGEL
\UR\ICA CEKINOVI]
Department of Histology and Embryology,
Faculty of Medicine, University of Rijeka
B. Branchetta 20, 51000 Rijeka, Croatia
Correspondence:
Pernjak Pugel Ester
Department of Histology and Embryology,
Faculty of Medicine, University of Rijeka
B. Branchetta 20, 51000 Rijeka, Croatia,
E-mail: esterp@medri.hr
Key words: Congenital Cytomegalovirus
infection, Brain, Development
Received July 22, 2010.
PERIODICUM BIOLOGORUM UDC 57:61
VOL. 113, No 1, 51–60, 2011 CODEN PDBIAD
ISSN 0031-5362
Review
cal impairments including deafness, mental and psycho-
motor retardation, blindness, microcephaly, hydrocepha-
lus, and cerebral calcifications (6–9). This recognition of
the clinical importance of invasive HCMV disease in the
setting of immunodeficiency and in children with conge-
nital HCMV has induced the development of a HCMV
vaccine as top priority for the 21st century by the US In-
stitute of Medicine (10).
PATHOGENESIS OF CMV INFECTION
IN DEVELOPING BRAIN
Congenital HCMV infection is a result of virus trans-
mission from infected mother to child in three possible
ways: intrauterine (transplacental), intrapartum (expo-
sure to virus in the genital tract) and post-natal (acquisi-
tion via breast milk). Systemic HCMV infection affects
majority of organ systems from which reticuloendothe-
lial and nervous system are most heavily affected. Symp-
toms of acute HCMV infection in newborns include
jaundice, hepatosplenomegaly, thrombocytopenia and
microcephaly. While affection of reticuloendothelial sys-
tem does not result in long term disabilities, infection in
developing central nervous system (CNS) causes signifi-
cant morbidity.
The exact route of CMV infection to developing CNS
is still insufficiently defined. Several mechanisms of vi-
rus entry into the brain parenchyma have been proposed
for different neurotropic viruses, including herpes vi-
ruses, based on the data extrapolated from both in vitro
experiments and the ones performed on animal models.
Following infection of an infant CMV establishes vire-
mia and colonizes different organs, including the brain.
Mechanisms of virus entry into the CNS are still insuffi-
ciently defined and several routes were proposed: infec-
tion of endothelial cells forming the blood-brain barrier
(BBB) and viral spread to astrocyte processes (11, 12); vi-
rus spread through cerebrospinal liquor and infection of
epithelial cells of the chorioid plexus (13)]; and infec-
tion via infiltration of monocytes. In early postnatal pe-
riod monocytes populate the brain to become microglia
cells (14). Since CMV replicates in monocytes (15), these
cells could serve as carrier of the virus entry into develop-
ing CNS. Moreover, CMV infection of endothelial cells
induces monocyte extravasations and infection which fa-
cilitates virus propagation into developing brain (16).
For different viruses, including CMV, the capability to
infect endothelial cells, the main structural elements of
BBB, pronouncedly facilitates the route for entering
brain parenchyma (17–20). Altered expression of tight
junctions, resulting in disintegration of the BBB, is ob-
served following viral infection of endothelial cells in
various viral infections (21–23), but data regarding BBB
disruption during congenital CMV infection are rare.
Studies performed by using Evans blue dye did not con-
firm the disruption of BBB following CMV infection of
newborn mice (24). Some explanation may be that BBB
in early postnatal (PN) period is still not completely ma-
ture, which is evident by decreased distribution of glu-
cose transporter (GLUT-1) in mice, one of the first BBB
markers on brain endothelial cells in the early postnatal
period (25). Minimum level of GLUT-1 expression is ob-
served at day 7 PN and reaches the level typical for ma-
ture BBB at day 14 PN. Other interendothelial junc-
tion-associated proteins: zonula occludens protein (ZO-1),
occludin and b-catenin also accomplish their adult ex-
tent at day 14 PN (25). Additional pathway of CMV en-
try into developing CNS is the infection of ependymal
cells of the chorioid plexus which leads to virus dissemi-
nation into the cerebrospinal fluid (CSF) and conse-
quent infection of brain parenchymal cells (13).
In a murine model of congenital HCMV infection pe-
ripheral inoculation of the virus into newborn mice re-
sults in systemic viremia characterized by both cell asso-
ciated and cell-free virus present in the blood (26). The-
refore virus CNS colonization by CMV after early post-
natal infection is mediated by both direct viral infection
of cells in contact to free virus and infiltration of infected
cells that actively populate developing brain.
Various aspects of the pathogenesis of CMV infection
in developing CNS are investigated by studying the cell
tropism, infectious dynamics of CMV infection and the
effects of CMV infection on proliferation, regeneration
and differentiation of neural cells. Both in vitro and in
vivo studies showed that human and animal neural pro-
genitor cells are fully permissive for CMV infection (27,
28). Studies performed on cultured human brain cells
showed that neurons present the site of persistent infec-
tion, while lytic infection occurs in glial cells (29). When
mature, neurons loose the susceptibility to CMV infec-
tion; in contrast to differentiated glial cells where viral
replication proceeds (30). Astrocytes, cells that constitute
majority of brain parenchyma, support virus replication
(31) while in microglia cells viral antigens can be de-
tected, but productive CMV infection cannot be deter-
mined (32).
HCMV in developing CNS induces focal, but wide-
spread non-necrotizing encephalitis (33, 34), character-
ized with typical pathohistological findings – foci of in-
fected cells coupled with inflammatory response (33).
Typical pathohistological lesions – glial nodules that sur-
round infected neurons frequently coupled with neuro-
nophagy, perivascular cuffing around endothelial cells,
mononuclear cell infiltration in both brain parenchyma
and meninges as well as periventricular necrosis are rea-
dily described in autopsied cases (35). Similarly, mouse
cytomegalovirus has shown the same pattern of patho-
logical findings in infected brain (24). Lytic infection of
both neurons and glial cells in mouse brain terminates
within three weeks post infection but pathohistological
lesions reside in the CNS for several months afterwards
(26). This argues for either virus persistence in the brain
that constantly primes immune response or consequent
development of immunopathology in this immunolo-
gicaly privileged organ (24).
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MECHANISMS OF NEURONAL
IMPAIREMENT IN CMV INFECTED
NEWBORN BRAIN
Imaging studies suggested greatly for HCMV infec-
tion involvement in neuronal impairment during early
development of the CNS (36–38). Congenital brain in-
fection can result in variety of neurological disorders
ranging from severe structural damage of the brain with
profound cognitive delays to disorders of perceptual sen-
ses such as hearing or visual loss. Most common finding
in autopsied infected infants is cerebellar hypoplasia (7),
while others include perivantricular calcifications, ven-
triculomegaly, delayed myelination, periventricular oc-
cipital cysts, lysencephaly, hippocampal dysplasia, white
matter glyosis and cortical neuron migration disorder
(39, 40). White matter lesions coupled with anterior tem-
poral lobe cysts on MR images are suggestive for CMV
infection (41). HCMV is thought to be the most com-
mon cause of acquired hearing loss in the US with up to
15% congenitally infected children exhibiting hearing
loss (42–45). Interestingly, retinitis associated with con-
genital HCMV infection can recur later in life, suggest-
ing that retina could be the site of viral persistence in
these patients.
Mechanisms of developing brain injury caused by
CMV are insufficiently understood, mostly due to the
limited number of autopsy cases with a comprehensive
description of the pathological changes detected in in-
fected infants. Virus-induced vasculitis might be respon-
sible for loss of vascular supply to regions of the develop-
ing brain, resulting in maldevelopment (35). Other in-
vestigators have postulated direct cytopathic effect of CMV
on developing neurons and glial cells (46) resulting in
impaired neuronal migration and cellular positioning
during postnatal brain development (7).
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Figure 1. Postnatal cerebellum development in newborn mice is impaired during perinatal MCMV infection. (A) During postnatal cerebellum de-
velopment in newborn mice granule cells in the outer part of the external granular layer (oEGL) proliferate and move into inner part of the EGL
(iEGL) where they differentiate in order to migrate into internal granular layer (IGL) of the cerebellar cortex. Proliferation and differentiation of
granule neurons is controlled by number of genes that are expressed either by Purkinje cells or granule cells itself. In parallel to proliferation of granule
neurons, Purkinje neurons arborize their dendrites in the molecular layer of the cerebellar cortex and form synapses with other neurons. (B) In
MCMV-infected newborn mice impaired proliferation and delayed migration of granule neurons from iEGL into IGL is observed, as well as im-
paired morphology of Purkinje cells. As a result (C) increased thickness of EGL and (D) decreased cerebellar area are observed, as compared to (E, F)
uninfected control mice. All figures present brains from 9 days old newborn mice. Cresyl violet staining. Magnifications 4x (D, F) and 10x (C, E).
For details of experimental procedure see the reference (24, 58).
Some evidence point out that HCMV replicates in the
placenta and can cause its inflammation and dysfunction
(47). This can indicate that congenital CMV disease is in
part a syndrome of placental insufficiency and that se-
quelae are developed as a result of systemic blood insuffi-
ciency to the fetus (48).
The investigation of in vivo pathogenesis and immu-
nology of HCMV infection in the CNS has been limited
by the strict species specificity of the virus. Murine CMV
(MCMV) shows significant homology in genomes, ex-
hibits conserved tissue tropism and temporal regulation
of gene expression and display similar pathogenesis to
HCMV infection (49), which allows the use of MCMV
as a model of human infection [50]. In the early postnatal
period (days 1–21) mouse cerebellum undergoes signifi-
cant morphological and developmental perturbances in
which granule neurons in the external granular layer
(EGL) proliferate and differentiate in order to migrate
into deeper parts of the cerebellar cortex, mainly into in-
ternal granular layer (IGL) (Figure 1A). This process is
strictly controlled by number of genes which are either
intrinsically expressed in granule neurons, or have ex-
trinsic effect on granule cell proliferation and differentia-
tion. These genes are mainly expressed by main neurons
of the cerebellum, Purkinje cells (51). A model of con-
genital MCMV infection extrapolated significant data of
MCMV involvement in neuronal impairment and al-
tered development of mouse cerebellum (24, 52). As de-
scribed by Koontz et al., MCMV infection in developing
CNS demonstrates huge developmental abnormalities
of the infected cerebellum in terms of delayed migration
of postmitotic neurons from EGL into IGL, impaired
morphology of Purkinje cells and decreased cerebellar
area as compared to uninfected mice (24) (Figure 1B, C,
D). Disruption of proliferation and differentiation of
granule cells in the EGL of MCMV-infected newborn
mice is manifested with decreased expression of TAG-1
(contactin-3) molecule and reduced expression of a sub-
unit of GABA A receptor (GABRA). Consequently, mi-
gration of granule cells is impaired and delayed lamina-
tion of cerebellar folia is observed (24). Purkinje cells
present with impaired arborization of its dendrites and
misslocalization outside of stratum gangliosum of devel-
oping cerebellar cortex. Studies on transgenic mice re-
vealed active spreading of the Purkinje cell somas from a
multilayered to a monolayer structure, and the orienta-
tion of dendrites towards the pial surface with the out-
growth of its dendritic branches is highly dependent on
the function and maturation of granule cells during post-
natal development of mouse cerebellum (53, 54). Ob-
served impairment in differentiation of granule neurons
in MCMV-infected newborn mice obviously influences
the maturation of Purkinje cells as well. Infected new-
born mice also exhibit a decreased expression of HOXa5,
a CNS patterning transcription factor of the hindbrain
region and decreased expression of TrkB, a high affinity
receptor for BDNF (brain derived neurotrophic factor), a
neurotrophin molecule that is involved in the promotion
of neuronal survival, as well as the regulation of both pre-
and postnatal development of the cerebellum (24).These
impairments result in a long term sequelae that are man-
ifested as reduced performance on a balance beam be-
havioral assessment and profound sensorineural hearing
loss in adult mice (unpublished data).
IMMUNE RESPONSE TO CMV INFECTION
OF THE CNS
Components of both cellular and humoral immune
response are involved in the control of CMV infection.
While CD8+ lymphocytes T have the main role in the
control of acute CMV infection, antibodies are essential
for protection from reactivation and virus dissemination
from latency (55, 56). CMV-specific antiviral response in
the CNS was mainly studied on the model of MCMV in-
54 Period biol, Vol 113, No 1, 2011.
Ester Pernjak Pugel and \ur|ica Cekinovi} Congenital CMV infection of CNS
Figure 2. MCMV-induced encephalitis in newborn mouse brain. (A)
MCMV-infected cells can be detected in brains of infected newborn
mice. Immunohistochemical staining with MCMV IE1-specific MAbs
reactive with MCMV IE1 protein is shown. Infection induces devel-
opment of encephalitis characterized with (B) mononuclear cell in-
filtration (Cresyl violet staining). Immunophenotypic analysis of
mononuclear cells infiltrations in infected mouse brain reveals that
(C, D) CD4+ T cells represent a minor immune population in
MCMV-infected newborn brain, while (E, F) CD8+ T cell predom-
inate in infected CNS. Magnifications 20x (C, E) and 40x (A, B).
Figure A presents the hippocampus of 9 day old infected newborn
mice. Figures B – F presented brains from mice on post natal day 17.
For details of experimental procedure see the reference (24, 58).
fection in newborn,or in adult immunodeficient mice
and involves activation of both innate and adaptive im-
munity (24, 52, 57, 58). In brains of MCMV-infected
newborn mice increased levels of: type I Interferons,
number of proinflammatory chemokines (for example
Interferon stimulated genes Ifit1 and 3, ISG12, ISG15,
members of LY6 family Ly6A/E molecules), toll like re-
ceptors (especially TLR-2), TNF-a and STAT-2 genes
are observed; as well as increased expression CXCL9 and
CXCL10 cytokines and MHC class I molecules (24). This
is followed by the activation of both innate and adaptive
cellular immune response comprised of NK cells, macro-
phages and lymphocytes T (24, 58, 59) (Figure 2).
Both astrocytes and microglia, the resident cells of the
CNS, are activated following infection in the brain pa-
renchima. In vitro MCMV replication in astrocytes is in-
hibited by TNF-a, IL-1b and IFN-g, while microglia
cells can support productive MCMV infection (60). Acti-
vated microglia and NK cells are detected in CMV-in-
fected newborn brain (24, 58). Microglia cells function as
an intrinsic immune system of the brain, and are consid-
ered to play a major role in traumatic lesions, neurodege-
nerative and infectious diseases in which survival of neu-
rons is compromised (61). During MCMV infection of
the CNS resident microglia cells secrete numbers of
proinflammatory cytokines and chemokines in order to
control the infection (62, 63). However there are evi-
dence for the role of this immune response in the develop-
mental impairment in infected CNS: TNF-a and IL-1b
are shown to be implicated in neuronal damage (64, 65).
Interestingly, in vitro infection of astrocyte cultures in-
duced secretion of the most potent anti-inflammatory
cytokine TGF-b (66). NK cells are primary cells that
control acute MCMV infection in adult mice (67), and
although detectable in the CNS of MCMV-infected new-
born mice, their role in the control of MCMV infection in
the CNS is still insufficiently defined. CD8+ T lympho-
cytes are major players that control MCMV infection in
newborn brain (58). CD8+ T cells present an effector
phenotype by secreting IFN-gamma, and infiltration of
these cells into the CNS results in the termination of pro-
ductive MCMV infection in brain parenchyma. While de-
pletion of CD8+ T lymphocytes in MCMV-infected pups
is associated with 100% mortality, these cells show pro-
tective capacity onto virus replication even in adult im-
munocompromised mice acutely infected with MCMV
(58). Conversely, in the brain of MCMV-infected adult,
immunocompromised mice CD4+ T lymphocytes were
identified as key cells that reduce the amount CMV in-
fection (57). Both CD4+ and CD8+ T cells isolated from
infected brain express high levels of PD-1 molecule, a
member of CD28 family of ligands that negativelly regu-
lates CD8+ T cell function. Engagement of PD-1 to its
ligands, PD-L1 and PD-L2, inhibits T cell proliferation
and cytokine production and is shown to be upregulated
on CD8+ T cells during other chronic infections like
LCMV or HIV (68, 69).
TREATMENT AND PREVENTION
OF CONGENITAL CMV INFECTION
Immunocompromised transplant recipients, HIV-in-
fected patients and fetuses are at high risk of developing a
serious and life-threatening CMV disease. Among these
the incidence of severe manifestations of CMV infection
are most prominent in infected infants. Children suffer-
ing acute HCMV infection in high percentage develop
widespread encephalitis and cerebellar maldevelopment
in terms of migration deficits of developing neurons and
impairment in foliation of cerebellar cortex. Although
preconceptual maternal immunity provides partial pro-
tection against CMV infection of the fetus (9, 70), high
rate of congenital CMV infection is still a major public
health problem. The highest rate of CMV transmission
from mother to child is during primary maternal infec-
tion, although transplacental transmission of the virus
can be seen in pregnant women with already established
preconception immunity. This setting is observed in se-
ropositive women infected with different CMV strains
(4, 71). Data regarding the role of preconceptual immu-
nity in the protection against congenital CMV infection
and subsequent development of neurological sequelae
are controversial. Some studies show that the presence of
maternal antibodies is associated with decreased rate of
congenital CMV infection and improved neurological
outcome of infected infants (72, 73). Others studies show
little, if any effect of maternal preconceptual immunity
on protection against virus-induced neurologic damage
in infected fetus following primary maternal infections,
or the rate of neurological sequelae in congenitally in-
fected infants (45, 74). Considering these data, treatment
of congenital CMV infection is necessary. Currently, four
drugs are licensed for use in treatment of systemic CMV
infection, all belonging to inhibitors of viral DNA poli-
merase: ganciclovir, valganciclovir, foscarnet and cidofo-
vir. From these, the first two are used in therapy of con-
genital CMV infection. Ganciclovir is the therapy of
choice for severe CMV disease in immunocompromised
adult patients but it is considered to be the best choice for
treatment of severe CMV infection in newborns (75). Al-
though data presenting efficacious postnatal therapy of
congenital CMV infection with this drug regarding long
term neurological development are faulty, recent study
performed in Alabama, USA, showed that treatment of
infected children with ganciclovir had a positive, protec-
tive impact on the cosequent development of hearing
loss (76). Ganciclovir medication is mutagenic, teratoge-
nic and carcinogenic, and there are still opposite stand-
points of the benefit from this treatment. The pharmaco-
kinetics of this drug and its success in the treatment of
severe complications of CMV infection in immunocom-
promised adults makes it a novel candidate for use in the
treatment of CMV infection in newborns (77).
Another approach of treatment in congenital HCMV
infection is the passive immunization of pregnant wo-
men with antibodies specific for HCMV. Intravenous in-
jection of HCMV hyperimmune globulin to pregnant
women suffering acute HCMV infection showed the
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protective effect on the rate of intrauterine transmission
of HCMV from mother to the developing fetus (78).
This protective effect of CMV immunoglobulins has still
to be confirmed by additional clinical studies. In a mu-
rine model of perinatal MCMV infection we have shown
that passive immunization of infected newborn mice
with either immune serum or immunoglobulins specific
for MCMV envelope glycoprotein gB reduces the rate of
MCMV infection in developing brain and improves the
neurological outcome in perinatally infected newborn
mice (26). Virus replication in brains of newborn mice
that received immune sera or antibodies specific for MCMV
gB was decreased to non-detectable levels, which was ac-
companied with reduced amount of inflammation. Most
importantly, parameters of postnatal cerebellum devel-
opment were highly improved in these mice, as com-
pared to controls (26).
Having in mind the high risk of infection in immuno-
compromised patients and infants, severity of sequelae
following infection in these populations and the lack of
efficacious and safe treatment, development of a CMV
vaccine has been declared as the highest priority in devel-
oped countries (79). So far, different immunization
strategies have been used to develop an efficacious vac-
cine against CMV infection for use in these high-risk
subjects. Development of a vaccine against congenital
CMV infection has been hampered by the species speci-
ficity of the virus. This has precluded the evaluation of
experimental vaccines against human CMV challenge in
animal studies. Different CMV vaccines have been con-
structed: live attenuated vaccines, vectored vaccines us-
ing viral vectors, protein subunit vaccines; peptide vac-
cines and DNA vaccines, from which live attenuated
vaccines and subunit vaccines have been tested in human
trials (Table 1). First tested among live attenuated vac-
cines was AD169 strain of the HCMV which showed to
induce virus-specific humoral respone, but no clinical
trials have been proceeded. Live attenuated Towne virus
as a vaccine candidate, on the other hand, is extensively
used in human clinical trials. Infection with this virus in-
duces both CD8+ T cell mediated immune response and
generation of virus-neutralizing antibodies at levels com-
parable to those induced in natural HCMV infection (80,
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TABLE 1
Designed CMV vaccines.
Vaccine Trial results (references)
Live attenuated
vaccines
Towne vaccine inefficient in prevention of CMV infection following transplanta-tion or transplacental infection (83)
Towne/Toledo vaccines well tolerated, ongoing studies in seronegative subjects (100)
AD169 vaccine first tested, induces HCMV-specific antibody response (101)
Subunit
vaccines
»vectored«
vaccines
gB/canarypox vectored vaccine (ALVAC) characterized as suboptimal immunogenic (94, 95)
gB/ie1/vaccinia Ankara vectored vaccine
(MVA)
not tested in human trials, induces humoral immunity in a
murine model (102)
pp65/canarypox vectored vaccine induces both humoral and cellular immune response (96)
pp65/alphavirus vectored vaccine not tested in human trials (99)
gM/gN (gcII complex) not tested in human trials (103)
gH/gL/gO (gcIII complex) not tested in human trials (103)
DNA vaccines
gB/pp65 bivalent DNA vaccine ongoing studies in hematopoietic stem cell transplant patients (104)
gB/pp65/ie1 trivalent DNA vaccine
As bivalent DNA vaccine, formulated using polomaxer adjuvant
CRL1005 and benzalkonium chloride Induces T cell response
against live attenuated CMV (Towne) (105–107)
Adjuvanted
protein vaccines gB/M59 adjuvant
ongoing studies in seronegative women, induces both humoral
and cellular immune response, good safety profile (90, 91, 108)
Preclinical vaccine approaches
Dense body
vaccines
enveloped, replication-defective particles
formed during CMV replication in cell cul-
tures
induce both humoral and cellular immune response in murine
models (109)
Nonstructural
genes DNA polymerase and helicase genes
tested in murine models elicits strong humoral and cellular im-
mune response (110)
Bacterial
artificial
chromosomes
recombinant vaccines with specific genomic
deletions or insertions which can improve the
safety profile of a candidate vaccine or modify
immune response
not tested in human trials, induces T cell response in guinea pig
model (111)
»Prime boost«
approach
priming with DNA vaccine is followed by
boosting with formalin-inactivated
viral particles
induces both humoral and CD8+ T cell immune response in ani-
mal models (103, 104)
81). Consequently, vaccination with this virus reduced
the risk of CMV infection, as well as the incidence of se-
vere CMV-induced disease in seronegative transplant re-
cipients and increased the probability of a graft accep-
tance in transplant patients (82). Towne virus does not
reactivate even in immunocompromised patients, does not
shed and does not produce viremia. However, in early
studies this vaccine did not prevent infection of mothers
of children excreting CMV (83).
In protein subunit vaccines, CMV-main immuno-
genic proteins are incorporated into a viral vector in or-
der to stimulate both humoral and cell-mediated im-
mune responses (84). Numerous CMVs antigens (pep-
tides) are characterized as capable to elicit strong specific
T cell response (85, 86). One of the first attempts using
peptides as vaccine candidates was an isolation of nine
amino-acid T-cell epitope and spliced into a vaccinia vi-
rus vector conjugated with hepatitis B core protein (87).
Vaccination with this virus elicited CD8+ T lymphocyte
antiviral response and protected against lethal disease in
a murine model; however it failed to induce humoral im-
munity. Among protein subunit vaccines the best pros-
pect for antiviral activity has the CMV immunodomi-
nant glycoprotein gB combined with adjuvant (MF59)
or expressed in cell lines. CMV infection typically in-
duces a serum antibody response to glycoprotein B (88)
and crucial epitopes for virus neutralization are con-
tained within conserved regions of this protein (89). Mo-
noclonal antibodies specific for gB neutralize both wild
type viral isolates and laboratory viral strains. In human
trials, vaccine containing gB coupled with MF59 adju-
vant induced high levels of antibody response, and inter-
estingly this effect was more prominent in infants than in
adults (90). Most importantly, recent data presented de-
creased incidence of maternal and congenital CMV in-
fection in women receiving vaccine containing glycopro-
tein gB coupled with MF59 adjuvant (91).
Another CMV protein that belongs to viral tegument,
pp65 has been used as a candidate for efficient CMV sub-
unit vaccine based on the findings of its strongest induc-
tion of the CD8+ T lymphocyte response (92, 93). Both
gB and pp65 have been expressed in a recombinant ca-
narypox ALVAC system (attenuated poxvirus which rep-
licates productively in avian species but abortively in
mammalian cells) and are shown to be immunogenic
and well tolerated (94–96). ALVAC expressing gB has
been tested in human trials and showed similar results in
the induction of antibody and cell-mediated immune re-
sponses as compared to humans vaccinated with CMV
gB/MF59 vaccine (95), while ALVAC expressing pp65
has showed to elicit CMV specific CD8+ T cell response
in CMV seronegative adults (96). Additional CMV vec-
tored vaccines utilize modified vaccinia virus and Vene-
zuelan equine encephalitis virus as vectors for either gB
or pp65 CMV proteins. These vaccines are predomi-
nantly tested in animal models. In MCMV model vac-
cinia recombinant expressing gB, when administered as
a vaccine, protected animals form lethal MCMV chal-
lenge (97). In guinea pig CMV (GPCMV) model gB vac-
cine partialy protected pups from congenital GPCMV
infection and in cases when the infection occurred, the
viral DNA load was decreased in pups born from gB-vac-
cinated mothers, as compared to controls (98). In the
same model, vaccination of dams with GP83 homolog of
the HCMV pp65 phosphoprotein coupled with Vene-
zuelan equine encephalitis virus followed by early tri-
mester GPCMV challenge resulted in improved preg-
nancy outcome and reductions in maternal blood viral
load (99). However, these vaccines have not yet been
tested in human trials. Ongoing studies are performed
using dense body vaccines, vaccines with nonstructural
genes, bacterial artificiral chromosomes and »prime boost«
approach (Table 1). Until rationale design of such prod-
ucts and preclinical testing in animal models is accom-
plished, a strategy for development and testing that is fo-
cused on human studies seems inherently flawed. We
would propose using preclinical studies in relevant ani-
mal models and a realistic goal – the generation of pro-
tective responses either by induction and/or transfer of
immunity that can protect the CNS from damaging in-
fection. This should be the primary goal for prevention
of significant disease from congenital HCMV infection.
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